Skip to main content
Top
Published in: Digestive Diseases and Sciences 10/2022

30-07-2022 | Pioglitazone | PROFILES AND PERSPECTIVES

DDS Perspective: Time to Get Serious About the Global Pandemic

Author: Rotonya M. Carr

Published in: Digestive Diseases and Sciences | Issue 10/2022

Login to get access

Excerpt

For many years now, the world has experienced a global pandemic—a disease that can be asymptomatic for some and for others account for significant morbidity and mortality. Indeed, this deadly pandemic’s culprit is responsible for nearly 400 deaths daily in the United States (US) alone [1]. Thirty-eight million adults in the US remain at risk of being affected [1]; and hospitalizations due to this pandemic have doubled in just a few years resulting in an estimated $23 billion in hospital costs [2]. And increasingly, young people and women are at risk [1]. While the World Health Assembly has recommended a global strategy to combat this pandemic [3], countries have only incompletely adhered to guidance. For example, preventive strategies in the US have been offered to only 8% of those most vulnerable to disease [4]. Perhaps these statistics appear familiar because of the COVID-19 pandemic we have battled since 2019; however, what I’ve outlined is the global pandemic that is alcohol-associated liver disease, or alcohol-related, liver disease (ALD). Eliminating the ALD pandemic will require a multifaceted approach involving robust public health policies, enhanced technology and education, and a shift toward therapies that address the early metabolic consequences of the disease. …
Literature
2.
go back to reference Hirode G, Saab S, Wong RJ. Trends in the burden of chronic liver disease among hospitalized US Adults. JAMA Netw Open 2020;3:e201997.CrossRef Hirode G, Saab S, Wong RJ. Trends in the burden of chronic liver disease among hospitalized US Adults. JAMA Netw Open 2020;3:e201997.CrossRef
3.
go back to reference World Health Organization Global strategy to reduce the harmful use of alcohol. 2010. World Health Organization Global strategy to reduce the harmful use of alcohol. 2010.
5.
go back to reference Termeie O, Fiedler L, Martinez L, et al. Alarming trends: mortality from alcoholic cirrhosis in the United States. Am J Med 2022 May 27:S0002–9343(22)00400–4. Online ahead of print. Termeie O, Fiedler L, Martinez L, et al. Alarming trends: mortality from alcoholic cirrhosis in the United States. Am J Med 2022 May 27:S0002–9343(22)00400–4. Online ahead of print.
6.
go back to reference Martinez P, Kerr WC, Subbaraman MS et al. New estimates of the mean ethanol content of beer, wine, and spirits sold in the United States show a greater increase in per capita alcohol consumption than previous estimates. Alcohol Clin Exp Res 2019;43:509–521.CrossRef Martinez P, Kerr WC, Subbaraman MS et al. New estimates of the mean ethanol content of beer, wine, and spirits sold in the United States show a greater increase in per capita alcohol consumption than previous estimates. Alcohol Clin Exp Res 2019;43:509–521.CrossRef
7.
go back to reference World Health Organization. The Global Health Observatory. World Health Organization. The Global Health Observatory.
8.
go back to reference Tapper EB, Parikh ND. Mortality due to cirrhosis and liver cancer in the United States, 1999–2016: observational study. BMJ 2018;362:k2817.CrossRef Tapper EB, Parikh ND. Mortality due to cirrhosis and liver cancer in the United States, 1999–2016: observational study. BMJ 2018;362:k2817.CrossRef
11.
go back to reference Im GY, Mellinger JL, Winters A et al. Provider attitudes and practices for alcohol screening, treatment, and education in patients with liver disease: a survey from the American Association for the study of liver diseases alcohol-associated liver disease special interest group. Clin Gastroenterol Hepatol 2021;19:2407–2416.CrossRef Im GY, Mellinger JL, Winters A et al. Provider attitudes and practices for alcohol screening, treatment, and education in patients with liver disease: a survey from the American Association for the study of liver diseases alcohol-associated liver disease special interest group. Clin Gastroenterol Hepatol 2021;19:2407–2416.CrossRef
12.
go back to reference Winters AC, Aby ES, Fix OK et al. Joining the fight: enhancing alcohol treatment education in hepatology. Clin Liver Dis (Hoboken) 2021;18:225–229.CrossRef Winters AC, Aby ES, Fix OK et al. Joining the fight: enhancing alcohol treatment education in hepatology. Clin Liver Dis (Hoboken) 2021;18:225–229.CrossRef
13.
go back to reference Pan AY, Zilberstein NF, Farnan JM et al. Recently graduated medical students lack exposure to and comfort with chronic liver diseases. Dig Dis Sci 2022;67:2081–2085.CrossRef Pan AY, Zilberstein NF, Farnan JM et al. Recently graduated medical students lack exposure to and comfort with chronic liver diseases. Dig Dis Sci 2022;67:2081–2085.CrossRef
14.
go back to reference Jeon S, Carr R. Alcohol effects on hepatic lipid metabolism. J Lipid Res 2020;61:470–479.CrossRef Jeon S, Carr R. Alcohol effects on hepatic lipid metabolism. J Lipid Res 2020;61:470–479.CrossRef
15.
go back to reference Buyco DG, Martin J, Jeon S et al. Experimental models of metabolic and alcoholic fatty liver disease. World J Gastroenterol 2021;27:1–18.CrossRef Buyco DG, Martin J, Jeon S et al. Experimental models of metabolic and alcoholic fatty liver disease. World J Gastroenterol 2021;27:1–18.CrossRef
16.
go back to reference Chen P, Torralba M, Tan J et al. Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice. Gastroenterology 2015;148:203–214.CrossRef Chen P, Torralba M, Tan J et al. Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice. Gastroenterology 2015;148:203–214.CrossRef
17.
go back to reference Dieperink E, Hauser P, Dockter K et al. Reduced alcohol use in patients prescribed pioglitazone. Am J Addict 2021;30:570–577.CrossRef Dieperink E, Hauser P, Dockter K et al. Reduced alcohol use in patients prescribed pioglitazone. Am J Addict 2021;30:570–577.CrossRef
18.
go back to reference Stopponi S, de Guglielmo G, Somaini L et al. Activation of PPARgamma by pioglitazone potentiates the effects of naltrexone on alcohol drinking and relapse in msP rats. Alcohol Clin Exp Res 2013;37:1351–1360.CrossRef Stopponi S, de Guglielmo G, Somaini L et al. Activation of PPARgamma by pioglitazone potentiates the effects of naltrexone on alcohol drinking and relapse in msP rats. Alcohol Clin Exp Res 2013;37:1351–1360.CrossRef
19.
go back to reference de la Monte SM, Pang M, Chaudhry R et al. Peroxisome proliferator-activated receptor agonist treatment of alcohol-induced hepatic insulin resistance. Hepatol Res 2011;41:386–398.CrossRef de la Monte SM, Pang M, Chaudhry R et al. Peroxisome proliferator-activated receptor agonist treatment of alcohol-induced hepatic insulin resistance. Hepatol Res 2011;41:386–398.CrossRef
20.
go back to reference van Bloemendaal L, IJzerman RG, Ten Kulve JS et al. GLP-1 receptor activation modulates appetite-and reward-related brain areas in humans. Diabetes 2014;63:4186–4196.CrossRef van Bloemendaal L, IJzerman RG, Ten Kulve JS et al. GLP-1 receptor activation modulates appetite-and reward-related brain areas in humans. Diabetes 2014;63:4186–4196.CrossRef
21.
go back to reference Vallof D, Maccioni P, Colombo G et al. The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents. Addict Biol 2016;21:422–437.CrossRef Vallof D, Maccioni P, Colombo G et al. The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents. Addict Biol 2016;21:422–437.CrossRef
23.
go back to reference Huang M, Kong B, Zhang M et al. Enhanced alcoholic liver disease in mice with intestine-specific farnesoid X receptor deficiency. Lab Invest 2020;100:1158–1168.CrossRef Huang M, Kong B, Zhang M et al. Enhanced alcoholic liver disease in mice with intestine-specific farnesoid X receptor deficiency. Lab Invest 2020;100:1158–1168.CrossRef
24.
go back to reference Iracheta-Vellve A, Calenda CD, Petrasek J et al. FXR and TGR5 agonists ameliorate liver injury, steatosis, and inflammation after binge or prolonged alcohol feeding in mice. Hepatol Commun 2018;2:1379–1391.CrossRef Iracheta-Vellve A, Calenda CD, Petrasek J et al. FXR and TGR5 agonists ameliorate liver injury, steatosis, and inflammation after binge or prolonged alcohol feeding in mice. Hepatol Commun 2018;2:1379–1391.CrossRef
26.
go back to reference Correnti J, Lin C, Brettschneider J et al. Liver-specific ceramide reduction alleviates steatosis and insulin resistance in alcohol-fed mice. J Lipid Res 2020;61:983–994.CrossRef Correnti J, Lin C, Brettschneider J et al. Liver-specific ceramide reduction alleviates steatosis and insulin resistance in alcohol-fed mice. J Lipid Res 2020;61:983–994.CrossRef
Metadata
Title
DDS Perspective: Time to Get Serious About the Global Pandemic
Author
Rotonya M. Carr
Publication date
30-07-2022
Publisher
Springer US
Keyword
Pioglitazone
Published in
Digestive Diseases and Sciences / Issue 10/2022
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-022-07628-z

Other articles of this Issue 10/2022

Digestive Diseases and Sciences 10/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.